Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Rating of “Hold” from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have received an average rating of “Hold” from the eight analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $6.75.

INO has been the subject of a number of recent research reports. Oppenheimer restated an “outperform” rating on shares of Inovio Pharmaceuticals in a research report on Friday, March 13th. Wall Street Zen upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th.

Institutional Trading of Inovio Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of INO. Janus Henderson Group PLC grew its holdings in shares of Inovio Pharmaceuticals by 1.3% in the fourth quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock worth $5,773,000 after purchasing an additional 42,146 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Inovio Pharmaceuticals by 35.0% in the third quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company’s stock worth $6,348,000 after buying an additional 703,727 shares during the period. Boxer Capital Management LLC purchased a new position in shares of Inovio Pharmaceuticals in the third quarter worth $5,382,000. Millennium Management LLC increased its stake in shares of Inovio Pharmaceuticals by 468.7% in the third quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company’s stock worth $4,616,000 after buying an additional 1,625,653 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Inovio Pharmaceuticals by 40.7% in the fourth quarter. Geode Capital Management LLC now owns 769,356 shares of the biopharmaceutical company’s stock worth $1,340,000 after buying an additional 222,609 shares during the period. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

NASDAQ:INO opened at $1.14 on Tuesday. The business has a 50 day moving average of $1.46 and a 200 day moving average of $1.77. The company has a market capitalization of $79.16 million, a price-to-earnings ratio of -0.68 and a beta of 1.43. Inovio Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Thursday, March 12th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.68. As a group, sell-side analysts anticipate that Inovio Pharmaceuticals will post -1.06 EPS for the current year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.